ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Effect of teplizumab on development of clinical (stage 3) type 1 diabetes

Effect of teplizumab on development of clinical (stage 3) type 1 diabetes
Shown are Kaplan-Meier estimates of the proportion of participants in whom clinical diabetes was not diagnosed. The overall hazard ratio was 0.41 (95% CI 0.22-0.78; two-sided p = 0.006 by adjusted Cox proportional-hazards model). The median time to diagnosis of type 1 diabetes was 48.4 months in the teplizumab group and 24.4 months in the placebo group. The numbers of participants with or without a diagnosis of clinical type 1 diabetes (upper right) represent data at the conclusion of the trial. Tick marks indicate censored data.
From: Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 2019; 381:603. Copyright © 2019 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
Graphic 81644 Version 4.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟